Evolent Health (EVH) shares are soaring 7.19% in pre-market trading on Friday, as the company receives positive attention from Wall Street analysts. The healthcare technology firm's stock is gaining momentum following upbeat analyst reports and a price target increase.
UBS analyst Kevin Caliendo has raised the firm's price target on Evolent Health to $15 from $14, while maintaining a Buy rating on the shares. This upgrade represents increased confidence in the company's growth prospects and potential for value creation.
Additionally, TD Cowen analyst Charles Rhyee reaffirmed a Buy rating on Evolent Health, setting a price target of $14.00. The consistent positive sentiment from multiple analysts is likely contributing to investor enthusiasm and driving the stock's pre-market surge.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。